Conclusions and Relevance
depressive disorder, depression, QTE
SECONDARY
In this QTE analysis of pooled clinical trial data from the FDA, antidepressants were found to confer a small reduction in depression severity that was broadly distributed across participants with severe depression. Alternatively, if the assumptions behind the QTE analysis are not met, then the data are also compatible with antidepressants eliciting more complete response in a smaller subset of participants than is suggested by this QTE analysis.This secondary analysis of pooled trial data evaluates the differences among randomized clinical trials in the outcomes of antidepressant monotherapy in patients with major depressive disorder.